These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 32471568)

  • 1. Response to Letter to the Editor by Yang et al.
    Hassan R; Sengupta M; Murai J; Pommier Y
    J Thorac Oncol; 2020 Jun; 15(6):e91. PubMed ID: 32471568
    [No Abstract]   [Full Text] [Related]  

  • 2. The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy.
    Yang H; Xu D; Gao Y; Schmid RA; Peng RW
    J Thorac Oncol; 2020 Jun; 15(6):e88-e90. PubMed ID: 32471567
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to letters to the editor by Brentisci et al. and Consonni and Mensi.
    Boffetta P; Righi L; Ciocan C; Pelucchi C; La Vecchia C; Romano C; Papotti M; Pira E
    Ann Oncol; 2019 Feb; 30(2):341. PubMed ID: 30534997
    [No Abstract]   [Full Text] [Related]  

  • 4. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
    Parrotta R; Okonska A; Ronner M; Weder W; Stahel R; Penengo L; Felley-Bosco E
    J Thorac Oncol; 2017 Aug; 12(8):1309-1319. PubMed ID: 28389374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on the paper 'Boffetta et al. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. Ann Oncol 2018; 29(2): 484-489'.
    Consonni D; Mensi C
    Ann Oncol; 2019 Feb; 30(2):340-341. PubMed ID: 30475941
    [No Abstract]   [Full Text] [Related]  

  • 6. Temozolomide: mechanisms of action, repair and resistance.
    Zhang J; Stevens MF; Bradshaw TD
    Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
    Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
    Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.
    Tentori L; Orlando L; Lacal PM; Benincasa E; Faraoni I; Bonmassar E; D'Atri S; Graziani G
    Mol Pharmacol; 1997 Aug; 52(2):249-58. PubMed ID: 9271347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Basis of Mesothelioma--More Than Asbestos Exposure.
    Lee D
    J Thorac Oncol; 2016 Feb; 11(2):e27-8. PubMed ID: 26845122
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
    Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
    Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds.
    Tentori L; Turriziani M; Franco D; Serafino A; Levati L; Roy R; Bonmassar E; Graziani G
    Leukemia; 1999 Jun; 13(6):901-9. PubMed ID: 10360379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.
    Tentori L; Lacal PM; Benincasa E; Franco D; Faraoni I; Bonmassar E; Graziani G
    J Pharmacol Exp Ther; 1998 May; 285(2):884-93. PubMed ID: 9580640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on 'Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy'.
    Brentisci C; Gangemi M; Migliore E; Mirabelli D; Stura A
    Ann Oncol; 2018 Dec; 29(12):2395-2396. PubMed ID: 30321262
    [No Abstract]   [Full Text] [Related]  

  • 14. Germline mutations in BAP1 impair its function in DNA double-strand break repair.
    Ismail IH; Davidson R; Gagné JP; Xu ZZ; Poirier GG; Hendzel MJ
    Cancer Res; 2014 Aug; 74(16):4282-94. PubMed ID: 24894717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma.
    Ladanyi M; Sanchez Vega F; Zauderer M
    Genome Med; 2019 Mar; 11(1):18. PubMed ID: 30914057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
    Malapelle U; Morra F; Ilardi G; Visconti R; Merolla F; Cerrato A; Napolitano V; Monaco R; Guggino G; Monaco G; Staibano S; Troncone G; Celetti A
    Lung Cancer; 2017 May; 107():41-49. PubMed ID: 27372520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
    Pacheco JM; Byers LA
    Cancer Discov; 2019 Oct; 9(10):1340-1342. PubMed ID: 31575562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic targeting of DNA repair in lung cancer.
    Lok BH; Rudin CM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22429-22431. PubMed ID: 31662477
    [No Abstract]   [Full Text] [Related]  

  • 19. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
    Liu X; Shi Y; Guan R; Donawho C; Luo Y; Palma J; Zhu GD; Johnson EF; Rodriguez LE; Ghoreishi-Haack N; Jarvis K; Hradil VP; Colon-Lopez M; Cox BF; Klinghofer V; Penning T; Rosenberg SH; Frost D; Giranda VL; Luo Y
    Mol Cancer Res; 2008 Oct; 6(10):1621-9. PubMed ID: 18922977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
    Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
    Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.